All In Biotech

Drug Trial Radar · NCT03050294

Evaluating Treatment Resistant Dermatitis TaroIIR

Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis

Last checked: Nov 20, 2026Latest source record: May 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Feb 1, 2017

Primary completion

Jun 1, 2017

Study completion Jun 1, 2017

Sponsor

Lead sponsor
Wake Forest University Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment.

Conditions

  • Atopic Dermatitis
  • Psoriasis

Interventions

  • Phone callsBehavioral

    Phone calls twice daily

  • Desoximetasone 0.25% sprayDrug

    Desoximetasone 0.25% spray applied twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator Global Assessment- Atopic DermatitisTime frame: 1 week
  2. Investigator Global Assessment- PsoriasisTime frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wake Forest University Health Sciences Department of Dermatology

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.